Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following ...

EpicentRx’s TGFß inhibitor, AdAPT-001 gets US FDA fast track designation for refractory soft tissue sarcoma treatment: La Jolla, California Saturday, December 7, 2024, 15:00 Hr ...

Discover the heightened thromboembolic risk for metastatic lung cancer patients on immune checkpoint inhibitors. Learn about ...

The Swiss company was evaluating tiragolumab with its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab) in patients with ...

Atezolizumab is a type of immunotherapy called a monoclonal antibody. It works by binding to PD-L1 proteins on the surface of cancer cells. This stops cancer cells from suppressing the immune system.

Tiragolumab is a novel immune checkpoint inhibitor ... or metastatic PD-L1 selected NSCLC. Participants were randomly assigned 1:1 to receive tiragolumab with atezolizumab or placebo with ...

A total of 20 intrahepatic cholangiocarcinoma patients were efficacy evaluable. The objective response rate (ORR) and disease control rate (DCR) were 25.0% and 80.0%, the median progression free ...

Tinengotinib is a novel multi-kinase inhibitor. It may play a role of synergistic effect when combined with ICI. The efficacy and safety data of tinengotinib in combination with atezolizumab in ...